Clarion call for trials assessing "cardiopulmonary" agents to reduce morbidity and mortality in inflammatory lung diseases.
Mancini
G B John
GB
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D011014:Pneumonia / Q000188:drug therapy / Q000453:epidemiology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000453:epidemiology*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate / Q000639:trends; D014481:United States / Q000453:epidemiology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors